Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A

ChemMedChem
Nicole RügerAndreas Link

Abstract

The JumonjiC-domain-containing histone demethylase 2A (JMJD2A, KDM4A) is a key player in the epigenetic regulation of gene expression. Previous publications have shown that both elevated and lowered enzyme levels are associated with certain types of cancer, and therefore the definite role of KDM4A in oncogenesis remains elusive. To identify a novel molecular starting point with favorable physicochemical properties for the investigation of the physiological role of KDM4A, we screened a number of molecules bearing an iron-chelating moiety by using two independent assays. In this way, we were able to identify 2-(1H-tetrazol-5-yl)acetohydrazide as a novel fragment-like lead structure with low relative molecular mass (Mr =142 Da), low complexity, and an IC50 value of 46.6 μm in a formaldehyde dehydrogenase (FDH)-coupled assay and 2.4 μm in an antibody-based assay. Despite its small size, relative selectivity against two other demethylases could be demonstrated for this compound. This is the first example of a tetrazole group as a warhead in JMJD demethylases.

References

Feb 1, 1995·Protein Engineering·A C WallaceJ M Thornton
Aug 10, 2005·Methods : a Companion to Methods in Enzymology·Birgit HeltwegManfred Jung
Jun 9, 2007·Biochemical and Biophysical Research Communications·Sook Shin, Ralf Janknecht
Jun 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Zhongzhou ChenGongyi Zhang
Jun 26, 2007·Nature Structural & Molecular Biology·Jean-François CoutureRaymond C Trievel
Feb 19, 2008·Nature Chemical Biology·Christoph Loenarz, Christopher J Schofield
Oct 24, 2008·Journal of Medicinal Chemistry·Nathan R RoseChristopher J Schofield
Oct 21, 2009·Chemical Communications : Chem Comm·Rok SekirnikChristopher J Schofield
Aug 6, 2010·Journal of Molecular Biology·Monica MantriChristopher J Schofield
Mar 18, 2011·ChemMedChem·Kai-Hsuan ChangNathan R Rose
Apr 5, 2011·EMBO Reports·Rasheduzzaman ChowdhuryAkane Kawamura
Sep 20, 2011·Analytical Biochemistry·Swathi KrishnanRaymond C Trievel
Oct 4, 2011·Journal of Experimental & Clinical Cancer Research : CR·Bei-Xu LiZi-Qin Zhao
Dec 3, 2011·Journal of Cellular Biochemistry·Tae-Dong KimRalf Janknecht
Jun 26, 2012·Journal of Medicinal Chemistry·Nathan R RoseAkane Kawamura
Aug 21, 2012·Molecular Oncology·Inga HoffmannManfred Jung
Sep 6, 2012·International Journal of Oncology·William L BerryRalf Janknecht
Mar 14, 2013·Expert Opinion on Drug Discovery·Felix Wilde, Andreas Link
Oct 1, 2013·Journal of Medicinal Chemistry·Joshua A Day, Seth M Cohen
May 27, 2014·Biochimica Et Biophysica Acta·Cyrille C ThinnesRichard J Hopkinson
Oct 4, 2014·Nature·Bo HeinemannKristian Helin
Jan 31, 2015·Cancer Genetics·Lissania Guerra-CalderasErnesto Soto-Reyes
Feb 27, 2015·Biological Chemistry·Weihua XuYong Peng

❮ Previous
Next ❯

Citations

Dec 29, 2015·Journal of Medicinal Chemistry·Tom E McAllisterChristopher J Schofield
Mar 25, 2017·Chemical Reviews·H Ümit KaniskanJian Jin
Jan 22, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Dong Hoon LeeSo Hee Kwon
Dec 12, 2018·Frontiers in Oncology·Christa Pfeifhofer-ObermairManfred Nairz
Dec 29, 2016·Molecular Diversity·Nicole RügerAndreas Link
Feb 19, 2021·Journal of Hematology & Oncology·Guan-Jun YangJiong Chen
May 30, 2021·Drug Discovery Today·Stephin BabyNagula Shankaraiah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.